Biocare to market Invitrogen’s breast cancer test in US
This article was originally published in Clinica
Invitrogen will make its newly-approved SPOT-Light HER2 CISH test kit available in the US with the help of Concord, California-based immunohistochemistry firm Biocare Medical. The latter will have exclusive distribution rights for that market. Financial terms of the deal were not disclosed. The test received pre-market approval from the FDA to assess the breast cancer patients who could benefit from receiving Herceptin (trastuzumab) in July this year (see Clinica No 1315, p 18). According to Invitrogen (Carlsbad, California), approximately one million people globally are screened each year for HER2 gene amplification or over-expression.